Alquest Support Yields FDA Approvals for Biotest Medical Diagnostics
Posted on: Tuesday, 26 August 2008, 12:01 CDT
Alquest has helped its client, Biotest Medical Diagnostics, earn biologics license application approvals through the Office of Blood Research and Review in the Center for Biologics Evaluation and Research of the FDA.
The FDA approvals covered biologics license application (BLA) submissions for 26 monoclonal antibody based blood grouping reagents, two anti-human globulin products, 13 reagent red blood cell products and supplements to three previously licensed reagents.
Alquest also performed statistical analysis of the clinical data for the final clinical report to support the license applications. In addition to preparing the BLAs, Alquest functioned as Biotest's US regulatory contact to support communications, interactions and responses with the FDA.
As a result, Biotest can now operate as a full service provider in the area of immunohaematology as one of only three companies to do so in the US.
Ann Quinlan-Smith, president of Alquest, said: "We are pleased to be able to support the commercialization of Biotest's exciting automated systems and blood grouping reagents. Our team worked diligently with Biotest staff over a period of two years to earn these approvals. We are proud of their professionalism and effort."
Source: Datamonitor
Related Articles
- AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
- DexCom(TM) Receives FDA Approval to Calibrate Its SEVEN(TM) Continuous Glucose Monitoring System Using Any FDA Cleared Blood Glucose Meter
- Redsense Medical Receives FDA Approval for Blood Loss Detection Device
- FDA Approves New Blood Typing Tests
- Pluristem Life Systems Retains Biologics Consulting Group to Pursue FDA Approval of PLX-1
- FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
- FDA Approves Higher Dose Formulations of Diovan HCT(R) (Valsartan/Hydrochlorothiazide) for Treatment of High Blood Pressure
- FDA Approves Merck's ROTATEQ(R), The Only Vaccine in the U.S. To Prevent Rotavirus Gastroenteritis
- FDA Approves the World's Smallest Diabetes Blood Glucose Monitor
- FDA Approves First Blood Test to Predict Risk for Stroke
 |
 |
User Comments (0)
RSS Feeds